November 6: Reimbursement Systems for Pharmaceuticals in Europe - In Person at ISPOR Europe 2022
Unlike marketing authorization for pharmaceuticals, mainly regulated at the European level by EMA, pricing and reimbursement decisions in Europe are managed by individual member states. Health care services are generally covered by a single public health insurer operating under the Ministry of Health supervision. As a monopoly buyer, this situation provides a leading position for the public health insurer to set reimbursement conditions. Therefore, based on each country’s set of regulations, processes, and values, wide variations exist in pricing and reimbursement decisions of pharmaceuticals. Using up-to-date governmental regulation sources and the ISPOR Global Health Care Systems Roadmap, this course will discuss health technology decision-making processes for reimbursement decisions for pharmaceuticals in France, Germany, Hungary, Italy, Poland, Spain, Sweden, and the UK. The course will describe these reimbursement systems, as well as compare, and bring into contrast their key characteristics. This course is designed for individuals with intermediate experience within a single healthcare system wishing to broaden their appreciation of other reimbursement systems.
Professor, Public Health
Faculté de Médecine, Laboratoire de Santé Publique
Aix-Marseille University
Marseille, France
November 6, 2022
Back to all short courses
Reimbursement Systems for Pharmaceuticals in Europe
LEVEL: Intermediate
TRACK: Health Policy & Regulatory
LENGTH: 8 Hours | Course runs 1 day
This short course will be offered in-person at the ISPOR Europe 2022 conference. Separate registration is required. Visit the ISPOR Europe 2022 website to register and learn more.
DESCRIPTION
Unlike marketing authorization for pharmaceuticals, mainly regulated at the European level by EMA, pricing and reimbursement decisions in Europe are managed by individual member states. Health care services are generally covered by a single public health insurer operating under the Ministry of Health supervision. As a monopoly buyer, this situation provides a leading position for the public health insurer to set reimbursement conditions. Therefore, based on each country’s set of regulations, processes, and values, wide variations exist in pricing and reimbursement decisions of pharmaceuticals. Using up-to-date governmental regulation sources and the ISPOR Global Health Care Systems Roadmap, this course will discuss health technology decision-making processes for reimbursement decisions for pharmaceuticals in France, Germany, Hungary, Italy, Poland, Spain, Sweden, and the UK. The course will describe these reimbursement systems, as well as compare, and bring into contrast their key characteristics. This course is designed for individuals with intermediate experience within a single healthcare system wishing to broaden their appreciation of other reimbursement systems.FACULTY MEMBERS
Mondher Toumi, MD, PhD, MScProfessor, Public Health
Faculté de Médecine, Laboratoire de Santé Publique
Aix-Marseille University
Marseille, France
Basic Schedule:
8 Hours | Course runs 1 Day